WellSpring's anti-nausea medication proves successful in market

SARASOTA, Fla, WellSpring Pharmaceutical on Tuesday announced that its anti-nausea liquid Emetrol is now the leading product in its category based on trailing 52-week sales ended Jan. 14, citing data from Information Resources Inc.

Over that 52-week period, Emetrol marketshare grew to 51.7% of the category based on sales growth of more than 24%.

WellSpring recently rolled out a national advertising campaign targeting women between the ages of 25 and 34, the company stated. And the National Association of Pediatric Nurse Practitioners recently selected Emetrol for editorial content in an upcoming issue.

“The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by pediatricians for children under their care, has proven to be one of the most important attributes of the brand,” stated WellSpring president and CEO Robert Vukovich.